UPDATE: Cowen Upgrades Sarepta Therapeutic (SRPT) to Outperform

September 20, 2016 6:41 AM EDT
Get Alerts SRPT Hot Sheet
Price: $32.66 -4.59%

Rating Summary:
    17 Buy, 10 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade SRPT Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
(Updated - September 20, 2016 8:48 AM EDT)

Cowen upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Market Perform to Outperform with a price target of $64 after the FDA approved Exondys 51.

Analyst Ritu Baral said, "Following today's approval of Exondys 51, SRPT announced average weight-based net, compliance adjusted price of ~$300k/yr but our estimated gross is much higher. SRPT looks ready to launch ASAP, with inventory/commercial operations/patient hub in place. We are upgrading with a new target of $64 based on a sound commercial plan to drive rapid, sticky sales, with upside from EU and the pipeline."

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $48.94 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Upgrades

Related Entities

Cowen & Co

Add Your Comment